deltatrials
Completed PHASE3 INTERVENTIONAL 3-arm NCT01722331

A Study to Evaluate the Efficacy and Safety of Subcutaneous MK-3222, Followed by an Optional Long-Term Safety Extension Study, in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-010) (reSURFACE 1)

A 64-Week, Phase 3, Randomized, Placebo-Controlled, Parallel Design Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222/MK-3222), Followed by an Optional Long-Term Safety Extension Study, in Subjects With Moderate-to-Severe Chronic Plaque Psoriasis (Protocol No. MK-3222-010)

Sponsor: Sun Pharmaceutical Industries Limited

Conditions Plaque Psoriasis
Interventions Matching Placebo Tildrakizumab 100 mg Tildrakizumab 200 mg
Updated 15 times since 2017 Last updated: Feb 23, 2022 Started: Dec 6, 2012 Primary completion: Oct 28, 2015 Completion: Nov 10, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Plaque Psoriasis, this trial is completed. The trial is conducted by Sun Pharmaceutical Industries Limited and has accumulated 15 data snapshots since 2012. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Aug 2018 · 31 days · monthly snapshot~Aug 2018 – ~Aug 2020 · 24 months · monthly snapshot~Aug 2020 – ~Sep 2020 · 31 days · monthly snapshot~Sep 2020 – ~Oct 2020 · 30 days · monthly snapshot~Oct 2020 – ~Jan 2021 · 3 months · monthly snapshot~Jan 2021 – ~May 2021 · 4 months · monthly snapshot~May 2021 – ~Jun 2021 · 31 days · monthly snapshot~Jun 2021 – ~Dec 2021 · 6 months · monthly snapshot~Dec 2021 – ~Apr 2022 · 4 months · monthly snapshot~Apr 2022 – ~Jul 2024 · 27 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 24 months · monthly snapshot

Change History

15 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  3. Apr 2022 — Jul 2024 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

  4. Dec 2021 — Apr 2022 [monthly]

    Active Not Recruiting PHASE3

  5. Jun 2021 — Dec 2021 [monthly]

    Active Not Recruiting PHASE3

▶ Show 10 earlier versions

  1. May 2021 — Jun 2021 [monthly]

    Active Not Recruiting PHASE3

  2. Jan 2021 — May 2021 [monthly]

    Active Not Recruiting PHASE3

  3. Oct 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE3

    Status: Completed → Active Not Recruiting

  4. Sep 2020 — Oct 2020 [monthly]

    Completed PHASE3

    Status: Unknown Status → Completed

  5. Aug 2020 — Sep 2020 [monthly]

    Unknown Status PHASE3

    Status: Active Not Recruiting → Unknown Status

  6. Aug 2018 — Aug 2020 [monthly]

    Active Not Recruiting PHASE3

  7. Jul 2018 — Aug 2018 [monthly]

    Active Not Recruiting PHASE3

  8. Jun 2018 — Jul 2018 [monthly]

    Active Not Recruiting PHASE3

  9. Feb 2017 — Jun 2018 [monthly]

    Active Not Recruiting PHASE3

  10. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE3

    First recorded

Dec 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Sun Pharmaceutical Industries Limited
Data source: Sun Pharmaceutical Industries Limited

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.